H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32

H.C. Wainwright analyst Joseph Pantginis maintains $Iovance Biotherapeutics(IOVA.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rat

Futu NewsJun 28 23:31 · Ratings

Iovance Biotherapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Iovance Biotherapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow JonesJun 28 23:08

Is It Too Late to Buy Iovance Biotherapeutics Stock?

Yahoo FinanceJun 28 16:05

Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma

First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced MelanomaSAN CARLOS, Calif

Iovance BiotherapeuticsJun 28 12:00

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delive

Iovance BiotherapeuticsJun 21 12:00

Iovance Biotherapeutics Is Maintained at Market Outperform by JMP Securities

Iovance Biotherapeutics Is Maintained at Market Outperform by JMP Securities

Dow JonesJun 20 19:54